Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
Recruiting
Phase 3
Interventional Study
Smoking Cessation
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 500 (estimated)
- Sponsor
- University of Kansas Medical Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study will evaluate the efficacy of extended bupropion(6 months) versus standard bupropion treatment (7 weeks) among African American daily smokers.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* African American
* age \>18 years
* interested in quitting
* smoked \>1 cpd for \>1 years
* smoked on \>25 days in the past month
* willing to take 6 months of study medication and complete all visits
* have a home address and functioning telephone number
Exclusion Criteria:
…
Contacts